Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 14/20 | 0.55 |
| ▸ | EGFR | P00533 | 14/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931692 | 0.87 | KDR (0.66) | CSF1REGFRKDRRETKIF5B | |
| SCHEMBL11931696 | 0.80 | KDR (0.78) | CSF1REGFRKDRRETKIF5B | |
| SCHEMBL12456408 | 0.79 | KDR (0.52) | EGFRKDRRETKIF5BFLT1 | |
| SCHEMBL11931699 | 0.79 | KDR (0.63) | EGFRKDRRETKIF5B | |
| SCHEMBL11931701 | 0.75 | KDR (0.69) | CSF1RKDRRETKIF5BFLT1 | |
| SCHEMBL6183306 | 0.73 | CSF1R (1.00) | CSF1REGFRKDRRETKIF5B | |
| Hydrochloric Acid SCHEMBL6180936 | 0.72 | CSF1R (1.00) | CSF1REGFRKDRRETKIF5B | |
| SCHEMBL11931700 | 0.72 | KDR (0.67) | KDRFLT1FLT4 | |
| SCHEMBL6181267 | 0.70 | CSF1R (0.80) | CSF1REGFRKDRRETKIF5B | |
| SCHEMBL11931690 | 0.70 | KDR (0.81) | CSF1RKDRFLT1FLT4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | FLT4, FLT1, CXCR4 | CSF1R 58/4885EGFR 768/4885KDR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.